ライフサイエンスコーパス: rivastigmine

1 histochemistry in the presence or absence of rivastigmine.

2 Almost twice as many patients on rivastigmine (37, 63%), than on placebo (18, 30%), showe

3 to placebo (59 assessed), those assigned to rivastigmine (55 assessed) had improved step time variab

4 Rivastigmine 6-12 mg daily produces statistically and cl

5 ested the effects of acute administration of rivastigmine, a central cholinesterase inhibitor, on pat

6 Rivastigmine, a cholinesterase inhibitor, was tested in

7 e present experiment assessed the ability of rivastigmine, a clinically utilized agent that inhibits

8 ntamine, the acetylcholinesterase inhibitors rivastigmine and donepezil did not potentiate nAChR-medi

9 cribed inhibition of acetylcholinesterase by rivastigmine and other carbamates as well as acylation o

10 ter drug discontinuation differences between rivastigmine and placebo tended to disappear.

11 cacy measures differed significantly between rivastigmine and placebo.

12 y was applied to the asymmetric synthesis of rivastigmine and the formal synthesis of several other p

13 The physostigmine, rivastigmine, and donepezil inhibition activities toward

14 t Alzheimer disease (donepezil, galantamine, rivastigmine, and memantine) improved scores on the ADAS

15 Three donepezil, two galantamine, one rivastigmine, and two memantine trials, comprising 3093

16 observed results for both nitroglycerin and rivastigmine at all times.

17 Rivastigmine, but not donepezil, was associated with gre

18 Rivastigmine can be used to treat symptomatic Parkinson

19 Rivastigmine can improve gait stability and might reduce

20 ange from baseline at week 76 was higher for rivastigmine capsules versus patch (10.6 +/- 2.9 vs -1.5

21 ange from baseline at week 76 was higher for rivastigmine capsules versus patch (10.6 2.9 vs -1.5 3.0

22 Individuals were given up to 12 mg rivastigmine daily or placebo for 20 weeks, followed by

23 e efficacy of compounds (e.g. physostigmine, rivastigmine, donepezil) which are able to inhibit in a

24 The cholinesterase inhibitors rivastigmine, donepezil, and metrifonate, which are devo

25 ndicated beneficial effects of donepezil and rivastigmine for cognitive and psychiatric symptoms.

26 130 patients and randomly assigned 65 to the rivastigmine group and 65 to the placebo group.

27 estinal side-effects were more common in the rivastigmine group than in the placebo group (p<0.0001);

28 o group (p<0.0001); 20 (31%) patients in the rivastigmine group versus three (5%) in the placebo grou

29 nd have implications for the recent trial of rivastigmine in sepsis-associated delirium.

30 Rivastigmine inhibited acetylcholinesterase in all posit

31 like other cholinesterase inhibitors tested, rivastigmine inhibited cholinesterases in normal and pat

32 In conclusion, rivastigmine is a potent inhibitor of acetylcholinestera

33 was to evaluate if the cognitive benefit of rivastigmine is affected by the presence of orthostatic

34 The cognitive benefit from rivastigmine is larger in patients with PDD with OH, pos

35 hus, at the therapeutic concentrations used, rivastigmine is likely to result in inhibition of pathol

36 The placebo-adjusted effect of rivastigmine on ADAS-Cog at week 24 was 5.6 +/- 1.2 for

37 The placebo-adjusted effect of rivastigmine on ADAS-Cog at week 24 was 5.6 1.2 for OH+

38 azard ratio (HR) for donepezil compared with rivastigmine or galantamine (cohort 1) was 0.95 (95% CI,

39 The adjusted HR for memantine vs rivastigmine or galantamine only (cohort 3) was 1.24 (95

40 y analysis, cohort 3 compared memantine with rivastigmine or galantamine only.

41 s prescribed donepezil with those prescribed rivastigmine or galantamine using the new-user design.

42 nit randomly assigned (1:1) patients to oral rivastigmine or placebo capsules (both taken twice a day

43 ed HR for memantine compared with donepezil, rivastigmine, or galantamine (cohort 2) was 1.03 (95% CI

44 ical trials, including at least 1 donepezil, rivastigmine, or galantamine treatment arm in patients w

45 Cohort 2 compared memantine with donepezil, rivastigmine, or galantamine using the prevalent new-use

46 mine versus placebo at week 24 (n = 501) and rivastigmine patch versus capsule at week 76 (n = 546).

47 Manipulating systemic acetylcholine (ACh) by rivastigmine reduced the time macaques waited to respond

48 In contrast, rivastigmine resulted in complete inhibition of butyrylc

49 use of pharmacologic agents (dexamethasone, rivastigmine, risperidone, ketamine, dexmedetomidine, pr

50 The overall prevalence of OH was lower for rivastigmine than placebo at week 24 (28.3% vs 44.6%, p

51 ng, anorexia) were seen more frequently with rivastigmine than with placebo, but safety and tolerabil

52 mean difference (95% CI -2.15 to -0.05) for rivastigmine to -2.17 for 10 mg daily donepezil (95% CI

53 hese findings and show cost-effectiveness of rivastigmine treatment.

54 rom 2 randomized controlled trials comparing rivastigmine versus placebo at week 24 (n = 501) and riv

55 The potency of rivastigmine was compared with those of other specific i

56 Rivastigmine was equipotent to the specific acetylcholin

57 Rivastigmine was uptitrated from 3 mg per day to the tar

58 Patients taking rivastigmine were significantly less apathetic and anxio

59 icit with the acetylcholinesterase inhibitor rivastigmine would reduce gait variability.